Publications en collaboration avec des chercheurs de Hospital Universitario Virgen del Rocío (41)

2024

  1. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

    The Lancet Infectious Diseases, Vol. 24, Núm. 4, pp. 375-385

2021

  1. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

    BMC Infectious Diseases, Vol. 21, Núm. 1

2020

  1. Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: The NEW_SAFE project

    BMJ Open, Vol. 10, Núm. 7

2019

  1. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects

    Journal of Neuroimmune Pharmacology, Vol. 14, Núm. 3, pp. 413-422

2017

  1. Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494

2016

  1. Sarcoidosis: an update on current pharmacotherapy options and future directions

    Expert Opinion on Pharmacotherapy, Vol. 17, Núm. 18, pp. 2431-2448

2015

  1. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884

2014

  1. Are hip hemiarthroplasty and total hip arthroplasty infections different entities? The importance of hip fractures

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 33, Núm. 8, pp. 1439-1448

  2. Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV

    The Lancet Infectious Diseases

  3. Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population

    PLoS ONE, Vol. 9, Núm. 5

  4. Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV/HCV coinfected patients

    PLoS ONE, Vol. 9, Núm. 7

  5. Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort

    International Journal of Infectious Diseases, Vol. 26, pp. 83-87

2013

  1. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis

    Clinical Infectious Diseases, Vol. 56, Núm. 11, pp. 1646-1653

  2. Reappraisal of the outcome of healthcare-associated and community-acquired bacteramia: A prospective cohort study

    BMC Infectious Diseases, Vol. 13, Núm. 1

2012

  1. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients

    Hepatology, Vol. 56, Núm. 4, pp. 1261-1270

  2. Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients

    AIDS, Vol. 26, Núm. 13, pp. 1721-1724

  3. Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: A propensity score-based analysis

    Antimicrobial Agents and Chemotherapy, Vol. 56, Núm. 1, pp. 472-478

  4. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis

    Clinical Infectious Diseases, Vol. 55, Núm. 12, pp. 1719-1726

  5. The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?

    Clinical Microbiology and Infection, Vol. 18, Núm. 7

2011

  1. Análisis descriptivo de las enfermedades asociadas a bacteriemia por Streptococcus bovis

    Medicina Clinica, Vol. 137, Núm. 12, pp. 527-532